CoChat

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial

Angelucci, Emanuele, Li, Junmin, Greenberg, Peter, Wu, Depei, Hou, Ming, Montaňo Figueroa, Efreen Horacio, Rodriguez, Maria Guadalupe, Dong, Xunwei, Ghosh, Jagannath, Izquierdo, Miguel, Garcia-Manero, Guillermo, on behalf of the TELESTO Study Investigators* · 2020 · Annals of Internal Medicine

The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.

Abstract

Background: Iron chelation therapy (ICT) in patients with lower-risk myelodysplastic syndromes (MDS) has not been evaluated in randomized studies. Objective: To evaluate event-free survival (EFS) and safety of ICT in iron-overloaded patients with low- or intermediate-1-risk MDS. Design: Multicenter, randomized, double-blind, placebo-controlled trial (TELESTO). (ClinicalTrials.gov: NCT00940602). Setting: 60 centers in 16 countries. Participants: 225 patients with serum ferritin levels greater than 2247 pmol/L; prior receipt of 15 to 75 packed red blood cell units; and no severe cardiac, liver, or renal abnormalities. Intervention: Deferasirox dispersible tablets (10 to 40 mg/kg per day) (n = 149) or matching placebo (n = 76). Measurements: The primary end point was EFS, defined as time from date of randomization to first documented nonfatal event (related to cardiac or liver dysfunction and transformation to acute myeloid leukemia) or death, whichever occurred first. Results: Median time on treatment was 1.6 years (interquartile range [IQR], 0.5 to 3.1 years) in the deferasirox group and 1.0 year (IQR, 0.6 to 2.0 years) in the placebo group. Median EFS was prolonged by approximately 1 year with deferasirox versus placebo (3.9 years [95% CI, 3.2 to 4.3 years] vs. 3.0 years [CI, 2.2 to 3.7 years], respectively; hazard ratio, 0.64 [CI, 0.42 to 0.96]). Adverse events occurred in 97.3% of deferasirox recipients and 90.8% of placebo recipients. Exposure-adjusted incidence rates of adverse events (≥15 events per 100 patient treatment-years) in deferasirox versus placebo recipients, respectively, were 24.7 versus 23.9 for diarrhea, 21.8 versus 18.7 for pyrexia, 16.7 versus 22.7 for upper respiratory tract infection, and 15.9 versus 0.9 for increased serum creatinine concentration. Limitations: The protocol was amended from a phase 3 to a phase 2 study, with a reduced target sample size from 630 to 210 participants. There was differential follow-up between treatment groups. Conclusion: The findings support ICT in iron-overloaded patients with low- to intermediate-1-risk MDS, with longer EFS compared with placebo and a clinically manageable safety profile. Therefore, ICT may be considered in these patients. Primary Funding Source: Novartis Pharma AG.

Overview

Integrity signals

Registry

Crossref · 10.7326/m19-0916

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Germing U, 2004, Haematologica, 89, 905

Cited by

See all 130

Metadata

Authors
Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montaňo Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., Garcia-Manero, G., & on behalf of the TELESTO Study Investigators*
Affiliations
  • Ospedale Policlinico San Martino (IT)
  • Shanghai Jiao Tong University (CN)
  • Stanford Medicine (US)
  • First Affiliated Hospital of Soochow University (CN)
  • Shandong University (CN)
  • Department of Hematology, Hospital General de México, Mexico City, Mexico (E.H.M.)
  • Mexican Social Security Institute (MX)
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (X.D., J.G.)
  • Novartis (Switzerland) (CH)
  • MD Anderson Cancer Center, University of Texas, Houston, Texas (G.G.)
Venue
Annals of Internal Medicine
Published
2020-04-21
Volume
172
Issue
8
Pages
513-522
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W3012730855
Cited by
120
References
38
Citations by year
2026: 13 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 24 · 2020: 12
FWCI
12.78
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
iron chelation therapy, deferasirox, myelodysplastic syndrome, iron overload, transfusion dependence, event-free survival, adverse events, cardiac dysfunction, liver dysfunction, acute myeloid leukemia transformation, serum ferritin, red blood cell transfusion, fever
MeSH terms
Deferasirox, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Blood Transfusion, Cause of Death, Double-Blind Method, Female, Ferritins, Humans, Iron Chelating Agents, Male, Middle Aged, Myelodysplastic Syndromes, Iron Overload, Young Adult, Patient Acuity, Transfusion Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial. https://app.cochat.ai/papers/10.7326/m19-0916
The paper
Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montaňo Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., Garcia-Manero, G., & on behalf of the TELESTO Study Investigators*. (2020). Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/m19-0916

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.